Isoliquiritigenin inhibits proliferation and induces apoptosis via alleviating hypoxia and reducing glycolysis in mouse melanoma B16F10 cells

Recent Patents on Anti-Cancer Drug Discovery

Volumn 11, Issue 2, 2016, Pages 215-227

  Wang, Yanming ^a,d   Ma, Jun ^a   Yan, Xinyan ^b   Chen, Xiaoyu ^c   Si, Lingling ^b   Liu, Ying ^b   Han, Jichun ^b   Hao, Wenjin ^a   Zheng, Qiu Sheng ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b SHIHEZI UNIVERSITY   (China)

^c NORTHWEST A F UNIVERSITY   (China)

^d Department of Respiratory medicine   (China)

Author keywords

Apoptosis; Glycolysis; Hypoxia; Isoliquiritigenin (ISL); Mouse melanoma B16F10 cells; Proliferation; Reactive oxygen species (ROS)

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ADENOSINE TRIPHOSPHATE; ENZYME; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOLIQUIRITIGENIN; LACTATE DEHYDROGENASE A; LACTIC ACID; LIPOCORTIN 5; MESSENGER RNA; PYRUVATE KINASE M2; REACTIVE OXYGEN METABOLITE; SULFORHODAMINE B; UNCLASSIFIED DRUG; CHALCONE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CELL STRUCTURE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; GLUCOSE METABOLISM; GLYCOLYSIS; HYPOXIA; MELANOMA; MELANOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL MELANOMA; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; TUMOR HYPOXIA;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOLYSIS; MELANOMA, EXPERIMENTAL; MICE; TUMOR HYPOXIA;

EID: 84966429063     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1573406412666160307151904     Document Type: Article

References (60)

1. Justus CR, Sanderlin EJ, Yang LV. Molecular connections between cancer cell metabolism and the tumor microenvironment. Int J Mol Sci 2015; 16(5): 11055-86.
2. Warburg O. On the origin of cancer cells. Science 1956; 123(3191): 309-14.
3. Elf S, Chen J. Targeting glucose metabolism in patients with cancer. Cancer. 2014; 120(6): 774-80.
4. Urifer, L., Nir, U., Shpungin, S. Drug combination comprising a glycolysis inhibitor and a tyronsine kinase inhibitor. WO201407296 (2014).
5. Young, C. C., Dario, C. A. Methods of controlling tumor bioenergetics networks. US20160015725 (2016).
6. Hielscher A, Gerecht S. Hypoxia and free radicals: Role in tumor progression and the use of engineering-based platforms to address these relationships. Free Radic Biol Med 2015; 79: 281-91.
7. Villa I E, Ricci JE. How does metabolism affect cell death in cancer? FEBS J 2015; 10. 1111: 13570
8. Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014; 123(17): 2663-72.
9. Yang Y, Karakhanova S, Hartwig W, D'Haese JG, Philippov PP, Werner J, et al. Mitochondria and mitochondrial ROS in cancer: Novel targets for anticancer therapy. J Cell Physiol. 2016; 10. 1002: 25349.
10. Zhang C, Jia X, Bao J, Chen S, Wang K, Zhang Y, et al. Polyphyllin VII induces apoptosis in HepG2 cells through ROS-mediated mitochondrial dysfunction and MAPK pathways. BMC Complement Altern Med. 2016; 16(1): 58.
11. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond). 2014; 11(1): 10.
12. Toyoda Y, Saitoh S. Adaptive regulation of glucose transport, glycolysis and respiration for cell proliferation. Biomol Concepts. 2015; 6(5-6): 423-30.
13. Jang Y, Han J, Kim SJ, Kim J, Lee MJ, Jeong S, et al. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation. Oncotarget. 2015; 6(35): 38127-38.
14. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015; 5(5): 378-89.
15. Gonzalez-Menendez P, Hevia D, Rodriguez-Garcia A, Mayo JC, Sainz RM. Regulation of GLUT transporters by flavonoids in androgen-sensitive and-insensitive prostate cancer cells. Endocrinology. 2014; 155(9): 3238-50.
16. Ashcroft, M., Jones, K. Antitumor HIF inhibitors patent. WO2015079213 (2015).
17. Won, M. S., Lee, K., Kim B. K., Ban, H. S., Son, S., Chung, K. S. Preparation of disubstituted adamantyl derivatives as HIF-1 inhibitors for suppressing cancer metastasis patent. WO2014084494 (2014).
18. Zhang MX, Hua YJ, Wang HY, Zhou L, Mai HQ, Guo X, et al. Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma. Oncotarget. 2016.
19. Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 2016; 16: 9.
20. Liu VM, Vander Heiden MG. The role of pyruvate kinase M2 in cancer metabolism. Brain Pathol 2015; 25(6): 781-3.
21. Jurisic V, Radenkovic S, Konjevic G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867: 115-24.
22. Daniele S, Giacomelli C, Zappelli E, Granchi C, Trincavelli ML, Minutolo F, et al. Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep. 2015; 5: 15556.
23. Xiao X, Huang X, Ye F, Chen B, Song C, Wen J, et al. The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep. 2016; 6: 21735.
24. Marini C, Salani B, Massollo M, Amaro A, Esposito AI, Orengo AM, et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle 2013; 12(22): 3490-9.
25. Gao Y, Xu D, Yu G, Liang J. Overexpression of metabolic markers HK1 and PKM2 contributes to lymphatic metastasis and adverse prognosis in Chinese gastric cancer. Int J Clin Exp Pathol. 2015; 8(8): 9264-71.
26. Das MR, Bag AK, Saha S, Ghosh A, Dey SK, Das P, et al. Molecular association of glucose-6-phosphate isomerase and pyruvate kinase M2 with glyceraldehyde-3-phosphate dehydrogenase in cancer cells. BMC Cancer. 2016; 16(1): 152.
27. Chen CY, Feng Y, Chen JY, Deng H. Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line. Bioorg Med Chem Lett. 2016; 26(1): 72-5.
28. Sun Y, Wang H, Liu M, Lin F, Hua J. Resveratrol abrogates the effects of hypoxia on cell proliferation, invasion and EMT in osteosarcoma cells through downregulation of the HIF-1α protein. Mol Med Rep 2015; 11(3): 1975-81.
29. Wu, S. S., Chen, Z., Xue, J. H., Yang, Y., Wang, J. Application of isoliquiritigenin in preparation of anti-inflammation medicines in prevention and treatment of hepatitis disease through inhibiting CXCL10 expression. CN104758274 (2015).
30. Honda H, Nagai Y, Matsunaga T, Okamoto N, Watanabe Y, Tsuneyama K, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol 2014; 96(6): 1087-100.
31. Wang, Z. H., Sun, C., Guo, L., Liu, J. H., Wang, T., Gan, L., Wang, X., F., Li, J., Zheng, Q. S. Use of isoliquiritigenin as medicament for preventing and treating or curing postoperative metastasis and relapse of malignant tumors. CN101658513 (2010).
32. Chen, S. Synergistic compositions consisting essentially of combinations of active agents selected from oridonin, wogonin, and isoliquiritigenin for the prevention of neoplasia. US009089546 (2015).
33. Lee SK, Park KK, Kim KR, Kim HJ, Chung WY. Isoliquiritigenin inhibits metastatic breast cancer cell-induced receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio in human osteoblastic cells. J Cancer Prev 2015; 20(4): 281-6.
34. Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y, Farajnia S. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res 2015; 93: 1-10.
35. Higo, H., Masuda, T. Process for producing isoliquiritigenin precursor. WO2016002848 (2016).
36. Wang, Z. H., Li, D. F., Cheng, H. M., Fu, W., Liu, T., Zhang, Y. K., Li, J., Zheng, Q. S. Application of isoliquiritigenin as cancer differentiating inducer. CN101627982 (2010).
37. Yuan X, Zhang B, Gan L, Wang ZH, Yu BC, Liu LL, et al. Involvement of the mitochondrion-dependent and the endoplasmic reticulum stress-signaling pathways in isoliquiritigenin-induced apoptosis of HeLa cell. Biomed Environ Sci 2013; 26(4): 268-76.
38. Yuan X, Yu B, Wang Y, Jiang J, Liu L, Zhao H, et al. Involvement of endoplasmic reticulum stress in isoliquiritigenin-induced SKOV-3 cell apoptosis. Recent Pat Anticancer Drug Discov 2013; 8(2): 191-9.
39. Chen X, Zhang B, Yuan X, Yang F, Liu J, Zhao H, et al. Isoliquiritigenin-induced differentiation in mouse melanoma B16F0 cell line. Oxid Med Cell Longev 2012; 2012: 534934.
40. Chen H, Zhang B, Yuan X, Yao Y, Zhao H, Sun X, et al. Isoliquiritigenin-induced effects on Nrf2 mediated antioxidant defence in the HL-60 cell monocytic differentiation. Cell Biol Int 2013; 37(11): 1215-24.
41. Ma C, Li G, Zhang J, Zheng Q, Fan X, Wang Z. An efficient combination of supercritical fluid extraction and high-speed countercurrent chromatography to extract and purify homoisoflavonoids from Ophiopogon japonicus (Thunb.) Ker-Gawler. J Sep Sci 2009; 32(11): 1949-56.
42. Liu, T., Wang, T., Cheng, H. M., Li, D. F., Guo, L., Zhao, W. B., Wang, Z. H., Zheng, Q. S. Temperature-controlled sustained-release injection containing isoliquiritigenin and preparation. CN101756888 (2010).
43. Han B, Chen W, Zheng Q, Wang X, Yan H, Li L, et al. Determination of isoliquiritigenin and its distribution in mice by synchronous fluorescence spectrometry. Anal Sci 2011; 27(11): 1115-9.
44. Wang W, Zhang Y, Lu W, Liu K. Mitochondrial reactive oxygen species regulate adipocyte differentiation of mesenchymal stem cells in hematopoietic stress induced by arabinosylcytosine. PLoS One. 2015; 10(3): e0120629.
45. Xin L, Wang J, Fan G, Che B, Wu Y, Guo S, et al. Oxidative stress and mitochondrial injury-mediated cytotoxicity induced by silver nanoparticles in human A549 and HepG2 cells. Environ Toxicol. 2015.
46. Cheng F, Yang Y, Zhang L, Cao Y, Yao W, Tang Y, et al. A Natural Triterpene Derivative from Euphorbia kansui Inhibits Cell Proliferation and Induces Apoptosis against Rat Intestinal Epithelioid Cell Line in vitro. Int J Mol Sci. 2015; 16(8): 18956-75.
47. Ramière C, Rodriguez J, Enache LS, Lotteau V, André P, Diaz O. Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol. 2014; 88(6): 3246-54.
48. Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015; 6: 7882.
49. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016.
50. Peng F, Du Q, Peng C, Wang N, Tang H, Xie X, et al. A review: The pharmacology of isoliquiritigenin. Phytother Res 2015; 29(7): 969-77.
51. Yang CS, Feng Q. Chemo/Dietary prevention of cancer: perspectives in China. J Biomed Res 2014; 28(6): 447-55.
52. Li D, Wang Z, Chen H, Wang J, Zheng Q, Shang J, et al. Isoliquiritigenin induces monocytic differentiation of HL-60 cells. Free Radic Biol Med 2009; 46(6): 731-6.
53. Zhao H, Yuan X, Li D, Chen H, Jiang J, Wang Z, et al. Isoliquiritigen enhances the antitumour activity and decreases the genotoxic effect of cyclophosphamide. Molecules 2013; 18(8): 8786-98.
54. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem. 2015; 116(5): 696-703.
55. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 2015; 356(2 Pt A): 156-64.
56. Zheng H, Li Y, Wang Y, Zhao H, Zhang J, Chai H, et al. Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion. Toxicol Appl Pharmacol. 2014; 280(1): 10-20.
57. Wang R, Zhang P, Li J, Guan H, Shi G. Ubiquitination is absolutely required for the degradation of hypoxia-inducible factor-1 alpha protein in hypoxic conditions. Biochem Biophys Res Commun. 2016; 470(1): 117-22.
58. Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol. 2016; 7: 52.
59. Schuster S, Boley D, Möller P, Stark H, Kaleta C. Mathematical models for explaining the Warburg effect: A review focussed on ATP and biomass production. Biochem Soc Trans 2015; 43(6): 1187-94.
60. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Targeting hypoxic response for cancer therapy. Oncotarget 2016.